У нас вы можете посмотреть бесплатно $115 Billion Rare Cannabinoid Leader | InMed Pharmaceuticals или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc.(Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug development. With the acquisition long since closed, the end results are starting to bear fruit. The company has already launched B2B sales of the rare cannabinoid cannabidivarin (CBDV) in the U.S. health and wellness sector. This is but a preview of additional product launches that will be introduced to the market in the coming quarters. Next up THCV is a cannabinoid chemical found in cannabis that shares similarities in molecular structure to THC, according to Jordan Tishler, M.D., a cannabis therapeutics specialist, instructor of internal medicine at Harvard Medical School, president of the Association of Cannabinoid Specialists, and CEO/CMO at inhaled. THCV has some structural elements that are different, which contribute to different effects. Timestamps: 0:00 Intro 1:03 BayMedica Acquisition 1:53 What Problems InMed Is Solving For Industry 4:43 The Importance Of CBD-V And THC-V 6:59 The First Company To Provide THCV To Market At Commercial Scale 8:37 THCV & The Cannabinoid Market Will Be Substantial 11:35 The Difference Between Delta 9 And Delta 8 12:54 Expectations On Cannabis Space 15:26 What Exactly Is An Analogue And The Importance Of It All? 17:57 Ongoing Discussions With BayMedica Related To The Industry 20:19 Jazz Pharmaceuticals Agreement To Acquire GW Pharmaceuticals 21:47 Finalizing About Channel: We are a business news platform that provides the latest and best insight on the stories making headlines around the world. We give Institutional and retail investors an inside edge in the competitive world of investing and profile companies that are making waves in their ever-growing industries. We are The Dales Report. Check out our website: https://thedalesreport.com/ Subscribe to our channel at https://article.thedalesreport.com/yo... Connect with us on our social media handles: Twitter: / thedalesreport Instagram: / thedalesrep... Tiktok: / thedalesrepor... Facebook: / thedalesreport TDR Contributors Instagram: Nicolle Hodges: / nicolledoublel Anthony Varrell: / anthonyvarrell _________________________________________________ The Dales Report Inc. disclosure policy applies to this video: https://thedalesreport.com/disclosure/